Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction – Results of the CHIARA MIA 2 trial

ConclusionFulacimstat was safe and well tolerated in patients with left-ventricular dysfunction (LVD) after first STEMI but had no effect on cardiac remodeling.
Source: American Heart Journal - Category: Cardiology Source Type: research